Tin tức & Cập nhật

Trastuzumab deruxtecan (T-DXd) at both 5.4 mg/kg and 6.4 mg/kg doses provides clinically meaningful and durable responses in patients with previously treated HER2-mutant (HER2m) metastatic non-small-cell lung cancer (mNSCLC), with the 5.4 mg/kg dose showing a more favourable benefit/risk profile, according to primary results of the phase II DESTINY-Lung02 trial.

Visceral fat area (VFA) is a reliable prognostic indicator of muscle mass and is associated with nutritional, immune, and inflammatory status in patients with diverse types of cancer, such as gastric, colorectal, and nonsmall-cell lung cancers (NSCLC), claims a recent study.

In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).

Pretreatment level of serum carcinoembryonic antigen (CEA) is independently associated with overall and disease-free survival among patients with nonsmall cell lung cancer (NSCLC), reports a study. The same marker is also used for the prognosis of patients with the same pathologic stages.

Patients with nonerosive gastroesophageal reflux disease (GERD) show no higher incidence of esophageal adenocarcinoma (EAC) when compared with the general population, according to a study.

In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).